MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required.
The call will be hosted by Alterity’s CEO Dr. David Stamler who will discuss the ATH434 efficacy data in primates released today along with recent clinical progress.
| Webcast details | ||
| AUSTRALIA PARTICIPANTS: | ||
| Date: | Wednesday, 6 December 2023 | |
| Time: | 9:00 a.m. AEDT (Sydney/Melbourne) | |
| UNITED STATES PARTICIPANTS: | ||
| Date: | Tuesday, 5 December 2023 | |
| Time: | 2:00 p.m. Pacific Time | |
| 5:00 p.m. Eastern Time | ||
Register here for the Zoom webcast
Registration is required and dial in details will be sent directly upon registration.
Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation. Investors are also able to submit questions in advance to Hannah Howlett at This email address is being protected from spambots. You need JavaScript enabled to view it.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
This email address is being protected from spambots. You need JavaScript enabled to view it.
+61 450 648 064
U.S.
Remy Bernarda
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 (415) 203-6386
| Last Trade: | US$1.11 |
| Daily Change: | -0.07 -5.56 |
| Daily Volume: | 13,109 |
| Market Cap: | US$9.790M |
November 12, 2024 November 06, 2024 October 11, 2024 October 02, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
